In sarcoma, the first operation decides everything. We make sure it’s the right one.
These rare tumours of muscle, bone and deep tissue punish improvisation. A lump shelled out casually can seed recurrence; a properly planned wide excision can cure outright. Our first task is often simply to slow things down — imaging, biopsy, plan — before any blade moves.
Why the first surgery matters most
Sarcomas are rare — which is exactly why generalised approaches fail them. They arise in soft tissues of limbs, trunk and retroperitoneum, in bone (osteosarcoma, Ewing’s — operated together with orthopaedic oncology), and as distinct entities like desmoid tumours and GIST.
The field’s hardest lesson is the “whoops procedure”: a lump enucleated without imaging or biopsy, assumed benign, later proven malignant — leaving tumour cells along the surgical track and forcing larger, riskier re-excision. Almost every one of those operations was preventable with a pause: an MRI, a core biopsy placed along the future incision line, a plan drawn before cutting.
So if you arrive here before any surgery — welcome; that is the ideal moment. And if a lump has already been removed elsewhere, bring whatever was done. Re-excision planning is a routine part of this practice, not an exception.
Warning signs that deserve a specialist’s eyes
Most lumps are harmless fat or cysts. The features below are what separate the ones worth investigating.
- ①A lump growing steadily over weeks or months.
- ②A lump lying deep — fixed within muscle rather than sliding with skin.
- ③Any lump larger than five centimetres — bigger than a golf ball.
- ④A painful lump, aching at night or without pressure.
- ⑤A lump recurring after previous removal — the single most telling sign.
- ⑥Limb swelling without injury, persistent and unexplained.
- ⑦A lump called a lipoma or ganglion that never actually had imaging before being labelled.
- ⑧Any planned lump excision without prior imaging or biopsy — pause and get a second opinion first. It costs days; skipping it can cost much more.
Tumours we treat
Rare deserves rarer still: coordinated care built around each entity’s biology.
◆Soft-Tissue Sarcoma — Limbs
The commonest sarcoma territory, where compartment-aware excision preserves function.
◆Trunk & Superficial
Chest and abdominal wall tumours excised with reconstructive planning from day one.
◆Retroperitoneal Sarcoma
Deep abdominal tumours requiring multivisceral resection and long-horizon follow-up.
◆Bone Sarcomas
Osteosarcoma and Ewing’s managed jointly with orthopaedic oncology and chemotherapy teams.
◆Desmoid Tumours
Aggressive-but-not-cancer growths demanding strategy between observation and surgery.
◆GIST
Gastrointestinal stromal tumours — targetable disease with highly effective tablet therapy.
Operations performed here
- ✦Wide compartment-aware excisionTumour removed inside its intact envelope with healthy margin — the principle that prevents recurrence.
- ✦Limb-salvage surgeryCuring limb sarcomas without amputation in the great majority of cases, function preserved deliberately.
- ✦Retroperitoneal multivisceral resectionDeep tumours removed together with involved organs when that is what completeness demands.
- ✦Re-excision of previously shelled-out lumpsCorrecting incomplete first operations with track removal and definitive margins.
- ✦Coordinated radiotherapy / chemotherapy pathwaysNeoadjuvant treatment arranged where shrinking tumours first makes surgery safer.
- ✦GIST managementSurgery sized to risk-score, followed by targeted therapy where mutation testing calls for it.
From first visit to full recovery
The pause
No lump is removed on impulse here — every case starts with review, not scissors.
MRI & staging
Deep anatomy mapped: compartments, vessels, neighbours.
Biopsy done right
Core biopsy placed along the future incision so nothing is contaminated.
Multidisciplinary plan
Orthopaedic oncology and radiation colleagues shape the sequence with us.
Surgery
Wide margins, reconstruction as needed, function designed back in.
Long surveillance
Sarcomas recur late — reviews continue for years, on schedule.
Families usually ask…
Because in this disease the initial operation sets the ceiling for every outcome after it. An unplanned excision can convert a curative situation into a recurrent one. Imaging plus biopsy plus plan takes one to two weeks; recovering from a “whoops procedure” takes far more than that.
In most modern limb sarcoma cases, no — limb-salvage surgery achieves cure rates comparable to amputation while keeping the limb working. When amputation genuinely offers more, we say so plainly and walk through rehabilitation honestly. Either way, function is engineered, not left to chance.
Removing the tumour surrounded by an intact cuff of healthy tissue — like taking a plum with its stone and some fruit around it, rather than scooping the plum out. Margins are measured by pathology afterwards and drive whether further treatment is needed.
Yes — but a special kind. Most GISTs respond remarkably to targeted tablets (imatinib) because their driver mutation is known. Surgery and medication work together, risk-scoring guides intensity, and outcomes today would have been unthinkable two decades ago.
If it has returned at the same spot, or the original report used words like “atypical”, bring the slides and scans for review — re-excision may be advised even for a benign-labelled lump if margins were inadequate. If the report was clear-cut and it hasn’t recurred, reassurance may be all you need.